RT Journal Article
SR Electronic
T1 Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21261042
DO 10.1101/2021.07.23.21261042
A1 Hamad Ali
A1 Abdelmohsen Al-Terki
A1 Sardar Sindhu
A1 Barrak Alahmad
A1 Maha Hammad
A1 Salman Al-Sabah
A1 Mohammad Alghounaim
A1 Mohammad H. Jamal
A1 Ali Aldei
A1 Mohammad J. Mairza
A1 Maitham Husain
A1 Sriraman Deverajan
A1 Rasheed Ahmad
A1 Preethi Cherian
A1 Irina Alkhairi
A1 Abdullah Alkandari
A1 Jehad Abubaker
A1 Mohamed Abu-Farha
A1 Fahd Al-Mulla
YR 2021
UL http://medrxiv.org/content/early/2021/07/26/2021.07.23.21261042.abstract
AB The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. Their levels were 154±49.1 vs. 138±59.4BAU/mL for IgG and 87.1±11.6 vs. 79.7±19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95%CI: −27.08 to −0.64BAU/ml, p=0.041) less IgG antibodies and 4.42% (95%CI: −8.53 to −0.32%, p=0.036) less neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis Study was funded by Kuwait Foundation for the Advancement of Sciences (KFAS) grant (RA HM-2021-008).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Ethical Review Committee of Dasman Diabetes Institute Protocol # RA HM-2021-008 as per the updated guidelines of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and of the US Federal Policy for the Protection of Human Subjects. The study was also approved by the Kuwait Ministry of Health ethical committee (reference: 3799, protocol number 1729/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request.